 ?您的位置：對照品 > 對照品 > 中藥對照品 > |
|
|
|
| 產(chǎn)品基本信息 |
|
| 產(chǎn)品編號(hào)：P840805 |
| 產(chǎn)品名稱：2-Pyrazinecarbonyl Chloride |
| 產(chǎn)品CAS：19847-10-0 |
| 規(guī)格含量：100mg |
| 產(chǎn)品價(jià)格：面議 |
| 聯(lián)系我們: |
 |
|
 |
|
|
| 產(chǎn)品詳細(xì)介紹 |
| 標(biāo)準(zhǔn)品編號(hào): |
P840805 |
| 名稱: |
2-Pyrazinecarbonyl Chloride |
| 別名: |
Pyrazine-2-carboxylic Acid Chloride; Pyrazinoic Acid Chloride; Pyrazinoyl Chloride; Pyrazinecarbonyl Chloride; |
| CAS號(hào): |
19847-10-0 |
| 分子式: |
C?H?ClN?O |
| 分子量: |
142.54 |
| 類別: |
Building Blocks; Miscellaneous; |
| 應(yīng)用: |
2-Pyrazinecarbonyl Chloride is an intermediate used in the synthesis of (S)-N-[1-(3-Hydroxy-3-methylbutanamido)-1-oxo-3-phenylpropan-2yl]pyrazine-2-carboxamide (H805105), which is an impurity of bortezomib (B675700), which is the first proteasome inhibitor to be approved by the US FDA for multiple myeloma, a blood cancer. A reversible inhibitor of the 26S proteasome-a barrel-shaped multiprotein particle found in the nucleus and cytosol of all eukaryotic cells. Targets the ubiquitin-proteasome pathway. |
| 參考文獻(xiàn) |
|
|
|
|
|
|
